Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach
- 26 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Lasers in Medical Science
- Vol. 27 (5), 1085-1090
- https://doi.org/10.1007/s10103-011-1029-4
Abstract
Acneiform rash associated with epidermal growth factor receptor inhibitors frequently presents facial manifestations. The treatment modality for such lesions still needs to be elucidated. The aim of this original report was to evaluate the effectiveness of high-level laser therapy in reducing the severity of facial acneiform rash induced by cetuximab, an epidermal growth factor receptor inhibitors. Four patients with metastatic colorectal cancer and two patients with head and neck cancer showing cetuximab-induced facial rash were treated by high-level laser therapy in two 8-min-long consecutive sessions/day over a 4-day treatment. Patients wore protective glasses to prevent eye damage related to laser light. Subsequently, patients were seen once a week for up to 21 days and after 180 days. During each day of treatment and each follow-up recall, patients were asked to complete a questionnaire about the onset and progression of their acneiform rash (for a total of eight sessions). Cetuximab-related toxicity and general discomfort visual analogue scales were also recorded in each of these eight sessions in the treated and control areas in each patient. After the fourth session of high-level laser therapy, the patients showed a noteworthy decrease in both cetuximab-related toxicity and visual analogue scales, up to a complete regression of the lesions at the end of the follow-up in all treated areas. The high-level laser therapy was effective in the healing of acneiform rash associated with epidermal growth factor receptor inhibitors with no side effects.Keywords
This publication has 32 references indexed in Scilit:
- Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or RadiotherapyThe Oncologist, 2011
- Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neckAnnals of Oncology, 2010
- EGFR Regulates the Expression of Keratinocyte-Derived Granulocyte/Macrophage Colony-Stimulating Factor In Vitro and In VivoJournal of Investigative Dermatology, 2010
- Hautreaktionen unter EGFR-Inhibitoren – Klinik und ManagementDeutsche Medizinische Wochenschrift (1946), 2010
- Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancerCutaneous and Ocular Toxicology, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- Chemotherapeutic agents and the skin: An updateJournal of the American Academy of Dermatology, 2008
- An Interdisciplinary Consensus on Managing Skin Reactions Associated With Human Epidermal Growth Factor Receptor InhibitorsClinical Journal of Oncology Nursing, 2008
- Two Cases of Acneiform Eruption Induced by Inhibitor of Epidermal Growth Factor ReceptorSkin Pharmacology and Physiology, 2007
- Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patientsJournal of the American Academy of Dermatology, 2006